Try GOLD - Free
Why global pharma companies choose India for GCCs
BioSpectrum Asia
|August 2024
India’s pharmaceutical industry is globally recognised for its capabilities in research and manufacturing and for its skilled labour. The country’s attractiveness as a destination for Global Capability Centres GCCs) is underpinned by several key factors, including cost-efficiency, a vast talent pool, robust infrastructure, and strong regulatory support.
India serves as a key global hub for development, attracting investments of more than $7 billion. Global pharmaceutical companies have established GCCs in India which serve as centres of excellence for drug discovery, formulation development, and healthcare solutions, while also supporting a strong ecosystem by employing talent and increasing the knowledge base.
For instance, Novartis has had a significant footprint in India since 1947, and in the last two decades, it has evolved to be an integral part of the development journey of many breakthrough medicines in various therapeutic areas like cardiovascular, oncology, immunology, neurology, and ophthalmology, amongst others. Similarly, MSD is primed to support the Indian government in protecting every woman through HPV vaccination with nearly 85 per cent of their products being manufactured locally. In India, Novo Nordisk is conducting phase 2-4 clinical trials across major disease areas with over 3,000 enrolled patients. With 37 ongoing trials in various therapy areas, India accounts for 7-8 per cent of Novo Nordisk's global patient pool. As GCCs have evolved to become centres for innovation and research, India has transformed into a hub for new product development for global enterprises. Consequently, over 50 per cent of the world's GCCs are now located in India, driven by factors that provide a competitive edge for businesses aiming to optimise operations and drive innovation.
Cost-efficiency of conducting business
India offers a compelling cost-quality ratio, making it financially advantageous for companies to establish their GCCs in the country. Labour costs in India are significantly lower than those in countries like North America and Europe, enabling companies to reduce operational expenses while maintaining profitability.
This story is from the August 2024 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
Alphamab Oncology appoints Fei Wang as Chief Financial Officer
Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market
DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
PHCbi introduces LiCellGrow Cell Expansion System
PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences
CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala
Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation
Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Argo Biopharma ropes in Dr Gena Wang as CFO and CSO
China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust
The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Korea designs model for accurate and scalable drug-drug interaction prediction
A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.
1 min
BioSpectrum Asia April 2027
Listen
Translate
Change font size
